27 - References

References

Schizophrenia and related psychoses CHAPTER 1 ■ ■Combined antipsychotic medications are commonly prescribed and this practice seems to be relatively resistant to change. ■ ■As a minimum requirement, all patients who are prescribed combined antipsychotic medications should be systematically monitored for adverse effects (including an ECG) and any beneficial effect on the symptoms of psychotic illness carefully documented. ■ ■Some antipsychotic polypharmacy strategies (e.g. combinations with aripiprazole) show clear benefits for tolerability but not efficacy. References

1. Harrington M, et al. The results of a multi-­centre audit of the prescribing of antipsychotic drugs for in-­patients in the UK. Psychiatr Bull 2002; 26:414–418.
2. Gallego JA, et al. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-­regression of global and regional trends from the 1970s to 2009. Schizophr Res 2012; 138:18–28.
3. Sneider B, et al. Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: a nation-­wide pharmacoepidemiological study. Eur Neuropsychopharmacol 2015; 25:1669–1676.
4. Procyshyn RM, et al. Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. J Clin Psychiatry 2010; 71:566–573.
5. Aggarwal NK, et al. Prevalence of concomitant oral antipsychotic drug use among patients treated with long-­acting, intramuscular, antipsychotic medications. J Clin Psychopharmacol 2012; 32:323–328.
6. Barnes T, et al. Antipsychotic long acting injections: prescribing practice in the UK. Br J Psychiatry Suppl 2009; 52:S37–S42.
7. Novick D, et  al. Antipsychotic monotherapy and polypharmacy in the treatment of outpatients with schizophrenia in the European Schizophrenia Outpatient Health Outcomes Study. J Nerv Ment Dis 2012; 200:637–643.
8. Paton C, et al. High-­dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. Br J Psychiatry 2008; 192:435–­439.
9. Royal College of Psychiatrists. Prescribing Observatory for Mental Health. Topic 1h & 3e: Prescribing of antipsychotic medication in adult mental health services, including high dose, combined, and PRN. CCQI 442. 2022 (last accessed February 2025); https://www.rcpsych.ac.uk/ improving-­care/ccqi/national-­clinical-­audits/pomh.
10. Correll CU, et  al. Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-­standing clinical practice. Psychiatr Clin North Am 2012; 35:661–681.
11. Baandrup L, et al. Association of antipsychotic polypharmacy with health service cost: a register-­based cost analysis. Eur J Health Econ 2012; 13:355–363.
12. Kadra G, et al. Predictors of long-­term (≥6months) antipsychotic polypharmacy prescribing in secondary mental healthcare. Schizophr Res 2016; 174:106–112.
13. Grech P, et al. Long-­term antipsychotic polypharmacy: how does it start, why does it continue? Ther Adv Psychopharmacol 2012; 2:5–­11.
14. Malandain L, et al. Correlates and predictors of antipsychotic drug polypharmacy in real-­life settings: results from a nationwide cohort study. Schizophr Res 2018; 192:213–218.
15. Fleischhacker WW, et al. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int J Neuropsychopharmacol 2014; 17:1083–1093.
16. Korkmaz Ş A, et al. Real-­world evidence of antipsychotic monotherapy versus polypharmacy in the treatment of schizophrenia spectrum disorders. J Clin Psychopharmacol 2024; 44:250–257.
17. Ortiz-­Orendain J, et al. Antipsychotic combinations for schizophrenia. Schizophr Bull 2018; 44:15–17.
18. Galling B, et al. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-­analysis and meta-­regression analysis. World Psychiatry 2017; 16:77–89.
19. Essock SM, et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry 2011; 168:702–708.
20. Hori H, et al. Switching to antipsychotic monotherapy can improve attention and processing speed, and social activity in chronic schizophrenia patients. J Psychiatr Res 2013; 47:1843–1848.
21. Shakir M, et al. The effect on relapse rate and psychiatric symptomatology: switching a combination of first-­ and second-­generation anti­ psychotic polypharmacy to antipsychotic monotherapy in long-­term inpatients with schizophrenia and related disorders: a pragmatic randomized open-­label trial (SwAP trial). Schizophr Res 2022; 243:187–194.
22. Constantine RJ, et al. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial. Schizophr Res 2015; 166:194–200.
23. Katona L, et al. Real-­world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nationwide study in Hungary. Schizophr Res 2014; 152:246–254.
24. Tiihonen J, et al. Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatry 2019; 76:499–507.
25. Goff DC. Can adjunctive pharmacotherapy reduce hospitalization in schizophrenia? Insights from administrative databases. JAMA Psychiatry 2019; 76:468–470.

26 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 26. Tiihonen J, et al. Real-­world effectiveness of antipsychotic treatments in a nationwide cohort of 29823 patients with schizophrenia. JAMA Psychiatry 2017; 74:686–693. 27. López de Torre A, et al. Antipsychotic polypharmacy: a needle in a haystack? Gen Hosp Psychiatry 2012; 34:423–432. 28. Carnahan RM, et al. Increased risk of extrapyramidal side-­effect treatment associated with atypical antipsychotic polytherapy. Acta Psychiatr Scand 2006; 113:135–141. 29. Gomberg RF. Interaction between olanzapine and haloperidol. J Clin Psychopharmacol 1999; 19:272–273. 30. Suzuki T, et al. Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-­label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. Hum Psychopharmacol 2008; 23:455–463. 31. Gallego JA, et al. Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf 2012; 11:527–542. 32. Hashimoto Y, et al. Effects of antipsychotic polypharmacy on side-­effects and concurrent use of medications in schizophrenic outpatients. Psychiatry Clin Neurosci 2012; 66:405–410. 33. Sorensen HJ, et al. Schizophrenia, antipsychotics and risk of hip fracture: a population-­based analysis. Eur Neuropsychopharmacol 2013; 23:872–878. 34. Dome P, et al. Paralytic ileus associated with combined atypical antipsychotic therapy. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:557–560. 35. Hedges DW, et al. New-­onset seizure associated with quetiapine and olanzapine. Ann Pharmacother 2002; 36:437–439. 36. Beelen AP, et al. Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone. Hum Exp Toxicol 2001; 20:215–219. 37. Eyles E, et al. Antipsychotic medication and risk of metabolic disorders in people with schizophrenia: a longitudinal study using the UK clinical practice research datalink. Schizophr Bull 2024; 50:447–459. 38. Baandrup L, et al. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-­based nested case–control study. J Clin Psychiatry 2010; 71:103–108. 39. Chen Y, et al. Antipsychotics and risk of natural death in patients with schizophrenia. Neuropsychiatr Dis Treat 2019; 15:1863–1871. 40. Tiihonen J, et al. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry 2012; 69:476–483. 41. Waddington JL, et al. Mortality in schizophrenia: antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-­year prospective study. Br J Psychiatry 1998; 173:325–329. 42. Kadra G, et al. Long-­term antipsychotic polypharmacy prescribing in secondary mental health care and the risk of mortality. Acta Psychiatr Scand 2018; 138:123–132. 43. Joukamaa M, et al. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 2006; 188:122–127. 44. Centorrino F, et al. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-­control study of risks versus benefits. Am J Psychiatry 2004; 161:700–706. 45. Taylor D, et al. Co-­prescribing of atypical and typical antipsychotics: prescribing sequence and documented outcome. Psychiatr Bull 2002; 26:170–172. 46. Kreyenbuhl J, et  al. Adding or switching antipsychotic medications in treatment-­refractory schizophrenia. Psychiatr Serv 2007; 58:983–990. 47. Nielsen J, et al. Psychiatrists’ attitude towards and knowledge of clozapine treatment. J Psychopharmacol 2010; 24:965–971. 48. Ascher-­Svanum H, et al. Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia. Neuropsychiatr Dis Treat 2012; 8:113–118. 49. Goren JL, et al. Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia. Psychiatr Serv 2013; 64:527–533. 50. Howes OD, et al. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry 2012; 201:481–485. 51. Thompson JV, et al. Antipsychotic polypharmacy and augmentation strategies prior to clozapine initiation: a historical cohort study of 310 adults with treatment-­resistant schizophrenic disorders. J Psychopharmacol 2016; 30:436–443. 52. Shiloh R, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine: a double-­blind, placebo-­controlled study. Br J Psychiatry 1997; 171:569–573. 53. Josiassen RC, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-­blind, placebo-­controlled trial. Am J Psychiatry 2005; 162:130–136. 54. Paton C, et al. Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-­analysis. J Clin Psychopharmacol 2007; 27:198–204. 55. Barbui C, et al. Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr Bull 2009; 35:458–468. 56. Taylor DM, et al. Augmentation of clozapine with a second antipsychotic: a meta-­analysis of randomized, placebo-­controlled studies. Acta Psychiatr Scand 2009; 119:419–425. 57. Fleischhacker WW, et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-­blind, placebo-­controlled trial. Int J Neuropsychopharmacol 2010; 13:1115–1125. 58. Cooper SJ, et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol 2016; 30:717–748. 59. Byerly MJ, et al. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-­titration with risperidone or olanzapine: analysis of a randomized, open-­label study. Schizophr Res 2009; 107:218–222. 60. Liu X, et al. Co-­prescription of aripiprazole on prolactin levels in long-­term hospitalized chronic schizophrenic patients with co-­morbid type 2 diabetes: a retrospective clinical study. Front Psychiatry 2023; 14:1124691.

Schizophrenia and related psychoses CHAPTER 1 61. Jiang Q, et al. Treatment of antipsychotic-­induced hyperprolactinemia: an umbrella review of systematic reviews and meta-­analyses. Front Psychiatry 2024; 15:1337274. 62. Shim JC, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-­induced hyperprolactinemia: a placebo-­ controlled trial. Am J Psychiatry 2007; 164:1404–1410. 63. Trives MZ, et  al. Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-­acting injection. J Clin Psychopharmacol 2013; 33:538–541. 64. Chen CK, et al. Differential add-­on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:1495–1499. 65. Lin SK. Antipsychotic polypharmacy: a dirty little secret or a fashion? Int J Neuropsychopharmacol 2020; 23:125–131. 66. Guinart D, et al. Antipsychotic polypharmacy in schizophrenia: why not? J Clin Psychiatry 2020; 81:19ac13118.